Pharma Mar, S.A. (PHM) Earnings Call Transcripts

Pharma Mar, S.A.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, PulteGroup, Inc. reported net new orders of 7,536 homes, a 6% increase year-over-year, and home sale revenues of $3.8 billion, reflecting an 8% decrease in closings. The company maintained its full-year guidance for closings between 28,500 and 29,000 homes, while gross margins improved to 25%. Management highlighted a successful transition back to build-to-order homes, which now represent 45% of new orders, indicating a strategic shift that could enhance profitability moving forward.

Reported metrics

Guidance from management

For Q3 2026, management expects to close between 7,000 and 7,400 homes and reaffirms full-year closings guidance of 28,500 to 29,000 homes. They anticipate average sales prices for the remainder of the year to be in the range of $550,000 to $560,000.

What management said

Great. Thanks, Ryan. We're now prepared to open the call for questions. So we can get to as many questions as possible during the remaining time of this call. We ask that you limit yourself to one question and one follow-up. Jordan, we'll start taking questions now.

Yes. I would say it's probably a fairly accurate assumption, John. We got a little bit of favorable mix in Q2 with just where closings came from that benefited the margin. maybe that goes back a little bit the other way in Q3. But as Jim highlighted, we're reiterating our full year guide. And so the fact that we're growing orders, we think we outperformed relative to order growth expectations in the most recent quart...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of demand amid macroeconomic uncertainties and the competitive landscape. There were questions about the potential for increased incentives in the second half of the year and the impact of community count growth on SG&A leverage.

Main topics on the call

• Net New Orders Growth — PulteGroup's net new orders increased by 6% year-over-year to 7,536 homes, with active adult orders rising by 12%. Management noted, "We realized higher orders across all buyer groups," indicating broad-based demand.
• Transition to Build-to-Order — The company successfully transitioned to a build-to-order model, with 45% of new orders classified as such, up from 39% in the prior year. This shift aligns with management's strategy to enhance customer choice and impro...
• Gross Margin Improvement — PulteGroup reported a gross margin of 25% for Q2, a sequential increase of 60 basis points. Management attributed this improvement to a favorable mix of closings and lower-than-anticipated discounts, stating, "We benefit...
• Community Count Growth — Community count increased by 8% year-over-year, with management maintaining guidance for a 3% to 5% increase for the full year. This growth is crucial for sustaining order momentum and revenue generation.

Read the full Pharma Mar, S.A. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 61 Pharma Mar, S.A. earnings call transcripts on record, spanning January 9, 2020 to July 30, 2026. Based on this history, Pharma Mar, S.A. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PHM

Exchange

BME

Country

ES

Sector

Health Care

Industry

Biotechnology

Calls on record

61

First call

January 9, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly